Managing Risk in a Patient with Recent ACS

Released On
July 3, 2018

Expires On
July 3, 2019

Media Type
Internet

Completion Time
30 minutes

Specialty
Cardiology

Topic(s)
Low-Density Lipoprotein

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by the National Lipid Association.

 

This activity is supported by an educational grant from Amgen and Merck Sharp & Dohme Corp.

Credit Available

  • Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed to meet the needs of lipidologists, internists, endocrinologists, and physician assistants with an interest in lipid management.

Program Overview

Managing Risk in a Patient with Recent ACS is an online clinic-focused activity based on real-life experiences as told by our expert faculty. The learner will walk-through the steps of making a challenging diagnosis and formulating a management plan with their assigned patient in a virtual clinic setting. The content of this online activity is based on the proceedings from the National Lipid Association’s live Translational Science of the LDL-Receptor Master’s Course that took place in Philadelphia, PA on May 17 – 18, 2017. Participation in the live master’s course is not required in order to adequately participate in this online activity.

Learning Objectives

At the Conclusion of this activity, participants should be able to:

  • Diagnose complex LDL receptor disorders.
  • Identify the genetic causes of LDL disorders, including the clinical implications of these genetic disorders.
  • Discuss modalities of therapeutic interventions to lower Lp(a) levels in plasma.
  • Evaluate the clinical effects, safety, and efficacy data for treatment options for LDL receptor disorders.
  • Demonstrate the role of current therapies for the treatment of LDL receptor disorders.
  • Formulate long-term comprehensive management plans for patients suffering from LDL receptor disorders.

Faculty

Anne C. Goldberg, MD, FNLA

Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Linda C. Hemphill, MD, FNLA

Instructor in Medicine
Harvard Medical School
Boston, MA

Peter H. Jones, MD, FNLA

Director, Division of Cardiology
Associate Professor of Medicine Co-director, Lipid Metabolism and Atherosclerosis Clinic Center for Cardiovascular Disease Prevention Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, TX

CREDIT DESIGNATION

CME credit provided by the National Lipid Association

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement

The National Lipid Association designates this enduring internet activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistant Credit Designation

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME.

Disclosures of Conflicts of Interest

Faculty

Goldberg, Anne

  • Consultant: OptumRX , Sanofi/Regeneron
  • Contracted Research: Amarin, Amgen, Genzyme/ ISIS Pharmaceuticals, ISIS (IONIS), Merck & Co., Inc., Pfizer, Regeneron, Regeneron/ sanofi-aventis
  • Scholarly Contributions: Merck & Co., Inc.

Hemphill, Linda

  • Contracted Research: Ionis, Regeneron/Sanofi
  • Consultant: Amgen, Regeneron

Jones, Peter

  • Consultant: Amgen Inc., Merck & Co., Inc., Regeneron and Sanofi

Staff/Reviewer

NLA

  • Not Applicable: NLA staff has nothing to disclose.

White, Thomas

  • Speaker: Amarin, Ionis, Janssen

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.

DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.